The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK

The goal of this observational study is to learn about the long-term effects of GLP1 agonists (weight loss jab, including Mounjaro) in patients with Bardet-Biedl Syndrome (BBS) who take GLP1 agonists to treat high body weight. The main question: Do GLP1 agonists effectively and safely lower body weight in patients with BBS when taken long-term, compared to patients not on these medications? The investigators look at the change (%) in weight during the observational periods.

NCT Number	NCT07602803
Lead Sponsor	The Queen Elizabeth Hospital
Conditions	Bardet-Biedl Syndrome
Enrollment	300 participants
Start Date	2023-01-01
Primary Completion	2026-04-01 (estimated)
Study Completion	2026-04-22 (estimated)
Updated on ClinicalTrials.gov	2026-05-27